Abstract 1433P
Background
Prospective and retrospective data support the use of Atezolizumab in combination with Bevacizumab, Carboplatin and Paclitaxel (ABCP) in patients with extensive non-small cell lung cancer with EGFR mutations after exhausting oral targeted therapy. The atezo-brain study showed CNS efficacy of upfront atezolizumab and platinum doublet in patients without EGFR or ALK alterations and untreated brain metastases (CNS mPFS 6.9 months). The clinical impact of ABCP in patients with brain metastases and EGFR or ALK alterations remains unknown. Here we aimed to quantify the clinical impact of ABCP in our patient population with actionable mutations and brain metastases.
Methods
Patients with actionable mutations and CNS disease treated at the Clatterbridge Cancer Centre with ABCP between 2019 and 2022 were identified. All patients had been consistently selected, monitored, and documented by the same team. Data was collected retrospectively. Progression-free survival (PFS) and Overall Survival (OS) were quantified from day 1 of cycle 1.
Results
19 patients had brain metastases at baseline, with an average age of 59 (range 32-77). 4 had ALK translocations, 2 had rare EGFR mutations and 13 had common EGFR mutations. 4 patients had received brain radiotherapy. 13 patients had asymptomatic brain metastases and 7 patients had well-controlled CNS symptoms. They all had an average of 11 cycles of treatment (median 7). Disease control was achieved in 14 patients (74%) with partial response in 9 of them (47%). There was a 94% concordance in intracranial vs extracranial response. All patients with CNS symptoms experienced a subjective improvement after an average of 13 days, although one patient was then noted to have CNS progression on brain MRI at week 9. The median PFS was 5.71 months (CNS mPFS 6.79 months) and the median OS was 11.21 months. Grade 3-4 toxicity leading to treatment modification occurred in 10 patients (53%), but none leading to treatment discontinuation.
Conclusions
Our data indicates CNS efficacy of ABCP regardless of the actionable mutation or previous CNS treatment, with frequent and quick responses. This supports the use of ABCP in patients with actionable mutations and untreated brain metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Clatterbridge Cancer Centre.
Funding
Has not received any funding.
Disclosure
C. Escriu: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Invited Speaker: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20